Member, Scientific Advisory Board
Dr Donald Ogilvie
Dr Ogilvie heads the Cancer Research UK MCRC Drug Discovery Unit in the Paterson Institute (University of Manchester, UK). He assumed the role in 2009 after a 20-year career in the pharmaceutical industry.
Dr Ogilvie obtained an MA in Biochemistry at Oxford before working at the John Radcliffe Hospital on the role of proteases in breast cancer, then on inherited connective tissue disorders which became the basis for his D Phil. His first industry role was in ICI, which became Zeneca then AstraZeneca. For most of his career, Donald has worked on cancer drug discovery and early clinical development and was directly responsible for delivery of ten novel cancer development compounds, several of which have progressed to Phase II and III clinical trials and one, so far, to FDA approval.